title: Additive ocular hypotensive effect of latanoprost and acetazolamide. A short-term study in patients with elevated intraocular pressure.
abstract: OBJECTIVE
  To investigate the additive ocular hypotensive effect of latanoprost on the intraocular pressure (IOP) reduction induced by a suboptimal dose of acetazolamide, a carbonic anhydrase inhibitor.
  
  
  METHODS
  A short-term, randomized, placebo-controlled, double-masked study.
  
  
  METHODS
  Twenty-four patients with glaucoma with elevated IOPs.
  
  
  METHODS
  Acetazolamide 250 mg twice daily from day 1 to day 18. Topical 50 micrograms/ml latanoprost or placebo eye drops bilaterally instilled once daily from day 4 to day 18.
  
  
  METHODS
  IOP, conjunctival hyperemia.
  
  
  RESULTS
  The mean IOP of 19.5 mmHg during acetazolamide treatment was further reduced to 16.8 mmHg after topical administration of latanoprost, i.e., a decrease of 2.9 +/- 2.8 mmHg (15%, P < 0.001). Administration of placebo to patients on acetazolamide resulted in an upward drift of 1.3 mmHg (6%, P = 0.03). A modest but statistically significant increase in conjunctival hyperemia was found in the latanoprost-treated group, but did not affect the masking.
  
  
  CONCLUSIONS
  This short-term study indicates that the combination of topically applied latanoprost and a suboptimal dose of systemic carbonic anhydrase inhibitor is useful in the management of glaucoma.
authors.affiliation: Glaucoma Center, University of Amsterdam, The Netherlands.
authors.forename: A H
authors.initials: AH
authors.lastname: Rulo
authors.forename: E L
authors.initials: EL
authors.lastname: Greve
authors.forename: P F
authors.initials: PF
authors.lastname: Hoyng
mesh_terms: D000086:Acetazolamide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000284:Administration, Oral; D000287:Administration, Topical; D000368:Aged; D002257:Carbonic Anhydrase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003228:Conjunctiva / Q000098:blood supply; D003229:Conjunctival Diseases / Q000139:chemically induced; D004311:Double-Blind Method; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005260:Female; D005902:Glaucoma, Open-Angle / Q000188:drug therapy*; D006801:Humans; D006940:Hyperemia / Q000139:chemically induced; D007429:Intraocular Pressure / Q000187:drug effects*; D000077338:Latanoprost; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000188:drug therapy*; D009883:Ophthalmic Solutions; D011461:Prostaglandins F, Synthetic / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D002257:Carbonic Anhydrase Inhibitors; D009883:Ophthalmic Solutions; D011461:Prostaglandins F, Synthetic; D000077338:Latanoprost; D000086:Acetazolamide